How has been the historical performance of Aspira Pathlab?

Answer:The historical performance of Aspira Pathlab shows significant improvement from March 2024 to March 2025.

Breakdown:
In the fiscal year ending March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in the previous year. Total operating income also rose to 22.00 Cr from 13.20 Cr. The company's total expenditure, excluding depreciation, increased to 18.83 Cr from 14.76 Cr, driven by higher raw material costs and employee expenses. Despite this rise in costs, Aspira Pathlab achieved an operating profit (PBDIT) of 3.56 Cr, a turnaround from a loss of 1.14 Cr in the prior year. Consequently, profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, leading to a profit after tax of 2.02 Cr compared to a loss of 2.67 Cr in March 2024. The earnings per share (EPS) reflected this positive trend, rising to 1.96 from -2.59. The operating profit margin improved significantly to 14.41% from -11.82%, while the profit after tax margin also turned positive at 9.18% compared to -20.23% the previous year. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with total liabilities also rising to 17.46 Cr from 14.71 Cr. The book value per share improved to 7.03 from 5.07, indicating a strengthening financial position. Overall, Aspira Pathlab demonstrated a robust recovery and growth in its financial performance over the year.